Goldman Sachs Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $36

Benzinga Newsdesk www.benzinga.com Positive 51.8%

Neg 0% Neu 0% Pos 51.8%

Goldman Sachs analyst Richard Law initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $36.